Pimitespib is a Small Molecule owned by Otsuka Pharmaceutical, and is involved in 12 clinical trials, of which 6 were completed, 4 are ongoing, and 2 are planned.

Pimitespib (TAS-116) is an ATP-competitive HSP90 inhibitor. It binds to HSP90 which leads to selective inhibition of cytosolic HSP90alpha/beta. Hsp90 needs to bind ATP in a pocket located in the N-terminal domain to exert its function. TAS-116 competes with ATP binding thereby freezing the chaperone cycle, which in turn decreases the affinity of Hsp90 for client proteins and leads to 26S proteasome-mediated oncogenic client protein degradation.

The revenue for Pimitespib is expected to reach a total of $182m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pimitespib NPV Report.

Pimitespib was originated by Taiho Oncology and is currently owned by Otsuka Pharmaceutical. Otsuka Holdings is the other company associated in development or marketing of Pimitespib.

Pimitespib Overview

Pimitespib (Jeselhy) belongs to a class of antineoplastic drugs. It is formulated as tablets for oral route of administration. Jeselhy is indicated for the treatment of gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy.

Pimitespib (TAS-116) is under development for the treatment of solid tumors including  metastatic pancreatic cancer, metastatic biliary tract cancer, metastatic lung cancer, HER2 negative breast cancer, small cell lung cancer, endometrial cancer, bladder cancer and non-small cell lung carcinoma. It is a small molecule administered orally. It is a HSP90 inhibitor.

It was under development for gastric cancer,HER2+ breast cancer, thymic carcinoma and solid tumor

Otsuka Holdings Overview

Otsuka Holdings (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies. The company’s product portfolio includes pharmaceutical products, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices and OTC products. It markets its products in North America, Europe, and Asia. Otsuka is headquartered in Chiyoda-ku, Tokyo, Japan.

The company reported revenues of (Yen) JPY1,498,276 million for the fiscal year ended December 2021 (FY2021), an increase of 5.3% over FY2020. In FY2021, the company’s operating margin was 10.3%, compared to an operating margin of 13.8% in FY2020. In FY2021, the company recorded a net margin of 8.4%, compared to a net margin of 10.4% in FY2020. The company reported revenues of JPY451,811 million for the third quarter ended September 2022, an increase of 4.1% over the previous quarter.

Quick View – Pimitespib

Report Segments
  • Innovator (NME)
Drug Name
  • Pimitespib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.